BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2013

View Archived Issues

PDL BioPharma acquires royalty rights and milestones for type 2 diabetes products from Depomed

Read More

Researchers at Bristol-Myers Squibb present novel inhibitors of endothelial lipase

Read More

InnoCore and Allergan expand collaboration to develop new medicines for ophthalmic diseases

Read More

Boehringer Ingelheim describes new GPR40 receptor agonists

Read More

Isis Pharmaceuticals patents novel antisense oligonucleotides

Read More

Anacor receives award from Department of Defense for new classes of systemic antibiotics

Read More

Qiagen and Clovis partner to develop companion diagnostic for lung cancer candidate

Read More

MedMira receives further U.S. Army funding to develop tests for transfusion transmitted diseases

Read More

Merck & Co.'s combination regimen for chronic HCV obtains FDA breakthrough therapy designation

Read More

Russian company completes initial clinical trial steps for ABP-560

Read More

Taiho presents TAS-121, a potent and selective EGFR inhibitor

Read More

Gene therapy company Spark Therapeutics spun out of The Children's Hospital of Philadelphia

Read More

Antisense oligonucleotide ISIS-560131 targets the androgen receptor and reduces tumor growth in vivo

Read More

ERP29, IKBKAP gene polymorphisms associated with breast cancer risk and clinical features

Read More

Pharmacokinetics and pharmacodynamics determined for CW-002 in healthy volunteers

Read More

Mouse model created for genetic susceptibility to both dementia and Parkinson's disease

Read More

Daiichi Sankyo discloses new SGLT1/SGLT2 inhibitors

Read More

Merck & Co. and ElexoPharm prepare novel CYP11B2 inhibitors

Read More

New MCH1 receptor antagonists reported by GlaxoSmithKline

Read More

Sucampo and Takeda begin pivotal trial of lubiprostone liquid formulation

Read More

Roche recaps progress of third quarter 2013

Read More

ViiV Healthcare submits NDA for single-tablet HIV regimen

Read More

Enrollment complete in phase III trial of ZS-9 for treatment of hyperkalemia

Read More

DBV Technologies and INSERM form collaboration to develop Viaskin for refractory hemophilia A

Read More

Epirus and Orygen Biotecnologia sign collaboration agreement for biotechnology products in Brazil

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing